 |
| Ticagrelor Market |
Ticagrelor is an oral antiplatelet drug used to prevent blood clots and decrease the risk of heart attack or stroke in people who have had symptoms of acute coronary syndrome. It works by reversibly blocking the action of platelets in forming a clot, helping prevent any unstable or ruptured plaques from causing heart attacks. The need for such antiplatelet drugs is growing due to the rising prevalence of coronary heart diseases and related disorders globally.
The global Ticagrelor Market is estimated to be valued at US$ 1285.83 Mn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The strong adoption of ticagrelor as an antiplatelet drug is one of the key
trends driving the market growth. Ticagrelor has been shown to be more
effective than the widely used antiplatelet drug clopidogrel in reducing
cardiovascular events in patients with acute coronary syndrome. It provides
quicker onset of action and more consistent inhibition of platelet aggregation
compared to clopidogrel. Additionally, ticagrelor does not require metabolic
activation in the liver like clopidogrel, making it a more suitable option for
patients who are poor metabolizers of clopidogrel. These advantages over
existing therapies have led to increased usage of ticagrelor by doctors,
contributing significantly to the market expansion.
Segment Analysis
The global ticagrelor market is dominated by the antiplatelet drug segment.
Ticagrelor is an antiplatelet drug of the P2Y12 platelet inhibitor class used
to reduce the risk of thrombotic cardiovascular events such as stroke or heart
attack in patients with acute coronary syndromes or prior heart attack.
Ticagrelor is more commonly used as an alternative to clopidogrel in patients
who cannot tolerate aspirin or who have a higher risk of thrombosis. The
antiplatelet drug segment holds a major share owing to the high usage of
ticagrelor for treatment of cardiac conditions.
Key Takeaways
The global Ticagrelor
Market Growth is expected to witness high growth over the forecast
period of 2023 to 2030. The global Ticagrelor Market is estimated to be valued
at US$ 1285.83 Mn in 2023 and is expected to exhibit a CAGR of 3.3% over the
forecast period 2023 to 2030.
Regional analysis:
North America region currently dominates the ticagrelor market and is expected
to continue its dominance over the forecast period. This is attributed to
growing prevalence of cardiovascular diseases and greater usage of antiplatelet
drugs like ticagrelor for treatment in the region. Europe is also expected to
hold a significant market share.
Key players:
Key players operating in the ticagrelor market are ANDRITZ Group, Honeywell
International Inc. (Maxon), Oilon Group, R.W. Beckett Corp, QED Combustion, and
Alzeta Corporation. ANDRITZ Group offers thermal treatment solutions for
industries including waste incineration, minerals, cement, glass, and others.
Honeywell International Inc. (Maxon) provides combustion management systems and
related equipment.
For more insights, read- https://www.ukwebwire.com/ticagrelor-market-trends-size-and-share-analysis/
0 Comments